Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
BioCardia’s data safety monitoring board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint. And so the California biotech is ...
Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...
AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As ...
BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results